What is the trade name of bosutinib/bosutinib?

Bosutinib/Bosutinib is a targeted drug used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Its trade name is mainly named by pharmaceutical companies based on market demand. In the international market, the originator drug of bosutinib is usually sold under the name "Bosulif". This brand name was launched by Pfizer. Its effectiveness and safety have been verified through multiple clinical trials, making it one of the important choices for the treatment of CML.

"Bosulif", as the trade name of bosutinib, is widely used in drug instructions, prescriptions and drug advertisements. Its use helps patients and medical staff better identify and communicate relevant treatment options. In many countries and regions, including the United States and some European countries, Bosulif is available in medical institutions and pharmacies, and patients can purchase it according to the recommendations of their doctors.

In addition to the trade names of the original drugs, there are also some generics of bosutinib on the market. These generics are usually produced by different pharmaceutical companies and may have different names. For example, Indian pharmaceutical companies such as Mylan produce bosutinib generics with the trade name BOSUTRIS. Although their active ingredients are the same as the original drug, these generics may use different trade names on the market due to their respective brand strategies.

It is worth noting that although generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, patients should be cautious when choosing due to differences in production processes and quality control. When using generic medicines, it is recommended to communicate fully with your doctor to ensure that the medicine selected meets your individual treatment needs and health condition.

Reference materials:https://www.bosulif.com/